We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

387 hedge funds and large institutions have $8.08B invested in Intra-Cellular Therapies Inc. in 2024 Q4 according to their latest regulatory filings, with 69 funds opening new positions, 133 increasing their positions, 138 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

131% more call options, than puts

Call options by funds: $25.4M | Put options by funds: $11M

130% more first-time investments, than exits

New positions opened: 69 | Existing positions closed: 30

50% more funds holding in top 10

Funds holding in top 10: 10 → 15 (+5)

14% more capital invested

Capital invested by funds: $7.12B → $8.08B (+$963M)

9% more funds holding

Funds holding: 355 → 387 (+32)

4% less repeat investments, than reductions

Existing positions increased: 133 | Existing positions reduced: 138

Holders
387
Holders Change
+32
Holders Change %
+9.01%
% of All Funds
5.1%
Holding in Top 10
15
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+50%
% of All Funds
0.2%
New
69
Increased
133
Reduced
138
Closed
30
Calls
$25.4M
Puts
$11M
Net Calls
+$14.4M
Net Calls Change
+$1.74M

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$40.5M
2
TCM
TimesSquare Capital Management
New York
+$33M
3
DTC
Deep Track Capital
Connecticut
+$32.8M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$13.6M
5
O
OrbiMed
New York
+$13.4M

Top Sellers

1
WA
Wasatch Advisors
Utah
-$49.3M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$39.4M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$37.2M
4
PA
Perceptive Advisors
New York
-$27.4M
5
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
-$14.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
PWA
376
Provenance Wealth Advisors
Florida
$1.34K – – –
MA
377
Montag & Associates
Georgia
$1.09K – – –
CSWM
378
Cassady Schiller Wealth Management
Ohio
$1.09K +$1.07K +13 New
SWM
379
Spire Wealth Management
Virginia
$1.09K +$1.07K +13 New
BF
380
BOK Financial
Oklahoma
$949 +$822 +10 New
CPG
381
Cornerstone Planning Group
New Jersey
$890 +$575 +7 New
Fifth Third Bancorp
382
Fifth Third Bancorp
Ohio
$835 – – –
SS
383
SBI Securities
Japan
$835 +$822 +10 New
RTC
384
Riverview Trust Company
Washington
$585 – – –
BBHC
385
Brown Brothers Harriman & Co
New York
$585 +$575 +7 New
MCM
386
MV Capital Management
Maryland
$168 – – –
LFG
387
Larson Financial Group
Missouri
$167 +$164 +2 New
EP
388
Eversept Partners
New York
– -$9.11M -124,491 Closed
Bank of Nova Scotia
389
Bank of Nova Scotia
Ontario, Canada
– -$3.59M -49,000 Closed
TC
390
TwinBeech Capital
New York
– -$3.35M -45,807 Closed
Tudor Investment Corp
391
Tudor Investment Corp
Connecticut
– -$2.3M -31,478 Closed
VPC
392
Vestal Point Capital
New York
– -$2.2M -30,000 Closed
KOCAA
393
Knights of Columbus Asset Advisors
Connecticut
– -$1.65M -22,533 Closed
AA
394
AlphaCentric Advisors
Puerto Rico
– -$1.46M -20,000 Closed
HWAM
395
Hennion & Walsh Asset Management
New Jersey
– -$1.09M -14,942 Closed
ACM
396
ADAR1 Capital Management
Texas
– -$980K -13,400 Closed
NYLIM
397
New York Life Investment Management
New York
– -$823K -11,247 Closed
SEC
398
Seven Eight Capital
New York
– -$786K -10,742 Closed
Los Angeles Capital Management
399
Los Angeles Capital Management
California
– -$730K -9,979 Closed
CP
400
CenterBook Partners
Connecticut
– -$525K -7,177 Closed
13 14 15
16
17

ITCI Hedge Fund Activity: Q4 2024 in Review

387 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2024, worth a combined $8.08B — up 14% from $7.12B a quarter earlier.

Buyers outnumbered sellers: 69 funds opened new ITCI positions and 30 closed out — a net gain of 39 holders — while 133 added to existing stakes and 138 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $40.5M. The largest seller was Wasatch Advisors, cutting an estimated $49.3M.

  • 387 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2024, up from 355 in Q3 2024.
  • Funds reported $8.08B of Intra-Cellular Therapies Inc. stock for Q4 2024, up 14% quarter-over-quarter.
  • 69 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2024 and 30 closed out, a net change of +39 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q4 2024 was Adage Capital Partners, an estimated $40.5M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q4 2024 was Wasatch Advisors, an estimated $49.3M sold.

Based on aggregated 13F filings for Q4 2024.